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Abstract: The COL11A1 human gene codes for the α1 chain of procollagen 11A1 and mature
collagen 11A1, an extracellular minor fibrillar collagen.
Under regular conditions, this gene and its derived products are mainly expressed by
chondrocytes and mesenchymal stem cells as well as osteoblasts. Normal epithelial
cells and quiescent fibroblasts from diverse locations do not express them.
Mesenchyme-derived tumours and related conditions such as scleroderma and
keloids, are positive for COL11A1/(pro)collagen 11A1 expression, as well as high
grade human gliomas/glioblastomas. This expression is almost absent in benign
pathological processes such as breast hyperplasia, sclerosing adenosis, idiopathic
pulmonary fibrosis, cirrhosis, pancreatitis, diverticulitis, and inflammatory bowel
disease. By contrast, COL11A1/(pro)collagen 11A1 is highly expressed by activated
stromal cells of the desmoplastic reaction of different human invasive carcinomas, and
this expression is correlated with carcinoma aggressiveness and progression, and
lymph node metastasis.
COL11A1 up-regulation has been shown to be associated to TGF-β1, Wnt and Hh
signalling pathways, which are especially active in cancer-associated stromal cells.
At the front of invasive carcinomas, neoplastic epithelial cells, putatively undergoing
epithelial-to-mesenchymal transition, and carcinoma-derived cells with highly
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
metastatic capabilities, can express COL11A1. Thus, in established metastases, the
expression of COL11A1/(pro)collagen 11A1 could rely on both the metastatic epithelial
cells and/or the accompanying activated stromal cells.
Conclusion: COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of
human carcinoma-associated stromal cells and carcinoma progression.
Response to Reviewers: Reviewer #1: The review titled "COL11A1/(pro)collagen 11A1 expression is a
remarkable biomarker of human invasive carcinoma-associated stromal cells and
carcinoma progression" details the current knowledge of this topic and reference 97
previous studies. The authors are have been involved with this research topic and
therefore can contribute with their own experience. The topic is important in cancer
biology and has clinical implications.
Reply to comments
The figures that are now included are suboptimal. Figure 1 and 2 should be
reconsidered with the aim of generating one figure with the necessary information.
We have now combined former Figures 1 and 2 in just one new Figure 1, which has
been redrawn, keeping  the information we have considered  as most relevant.
Figure 3 is unclear and does not convey the information provided in text that both
stromal and epithelial cells within the tumor may express col11a1.
We have partially redrawn former Figure 3  -now Figure 2- , making a reference to the
putative expression of COL11A1/(pro)collagen11A1  in the epithelial front of invasive
carcinomas.
The example of immunohistochemistry (fig. 4) could be improved given the authors
previous experience. The Authors could display examples of human primary tumors
(and stroma) as well as cell lines.
We have now added more photos of examples of the expression of procollagen 11A1
in different kind of human tumors and cell lines   -new Figure 3-.
Some data on different tumors could be shown with a table, which could facilitate
comparative analysis.
We have now tried to summarize in a new Table 1 the up-regulation of
COL11A1/(pro)collagen 11A1 expression in different human tumours, according to the
current  literature.
There are 9 authors listed: this is unusual for a review paper. What are the
contributions of all these authors?
This review was intended as an update of those aspects of the biology of
COL11A1/(pro)collagen 11A1 in which our team has been involved for the last years. It
is the result of experimental observations, clinical findings, literature revisions and
discussions, in which all of us have participated and have been actively engaged. For
these reasons, we think that all the members of our team are entitled to be
acknowledged as authors.
Reviewer #3 :  The presented article is perfectly writed, designed, explained and
defended. For myself I find no more comments to add.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Reply to comments
 Perhaps slightly revise of the abstract since its reading becomes a little difficult
because is so sketchy.
According to Reviewer #3 comment(s), we now provide a longer version of the Abstract
to make it easier to read.
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Abstract 1 
The COL11A1 human gene codes for the α1 chain of procollagen 11A1 and mature 2 
collagen 11A1, an extracellular minor fibrillar collagen. 3 
Under regular conditions, this gene and its derived products are mainly 4 
expressed by chondrocytes and mesenchymal stem cells as well as osteoblasts. Normal 5 
epithelial cells and quiescent fibroblasts from diverse locations do not express them.  6 
Mesenchyme-derived tumours and related conditions such as scleroderma and 7 
keloids, are positive for COL11A1/(pro)collagen 11A1 expression, as well as high grade 8 
human gliomas/glioblastomas. This expression is almost absent in benign pathological 9 
processes such as breast hyperplasia, sclerosing adenosis, idiopathic pulmonary fibrosis, 10 
cirrhosis, pancreatitis, diverticulitis, and inflammatory bowel disease. By contrast, 11 
COL11A1/(pro)collagen 11A1 is highly expressed by activated stromal cells of the 12 
desmoplastic reaction of different human invasive carcinomas, and this expression is 13 
correlated with carcinoma aggressiveness and progression, and lymph node metastasis. 14 
COL11A1 up-regulation has been shown to be associated to TGF-β1, Wnt and 15 
Hh signalling pathways, which are especially active in cancer-associated stromal cells. 16 
At the front of invasive carcinomas, neoplastic epithelial cells, putatively 17 
undergoing epithelial-to-mesenchymal transition, and carcinoma-derived cells with 18 
highly metastatic capabilities, can express COL11A1. Thus, in established metastases, 19 
the expression of COL11A1/(pro)collagen 11A1 could rely on both the metastatic 20 
epithelial cells and/or the accompanying activated stromal cells. 21 
Conclusion: COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of 22 
human carcinoma-associated stromal cells and carcinoma progression. 23 
 24 
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 3 
(Pro)collagen 11A1 structure and normal tissue distribution  1 
 2 
The COL11A1 human gene codes for the α1 chain of procollagen and mature 3 
collagen of type XI, which is an extracellular minor fibrillar collagen. 4 
Each collagen protomer is usually made of three different polypeptides, designed 5 
as α1, α2, and α3, and coded by specific gene sequences. In collagen of type XI, the α1 6 
and α2 chains are coded by the COL11A1 and COL11A2 genes, respectively; however, 7 
the α3 chain is identical to α1(II), coded by the COL2A1 gene, which is the main 8 
component of collagen of type II. These polypeptides are synthesized as procollagens, 9 
which include the globular N- and C-propeptides flanking the prototypical collagen 10 
triple helix. Upon secretion, the propeptides are excised by proteolytic cleavage; at the 11 
ends of the triple-helical collagen molecule, short N- and C-telopeptides remain [1]. 12 
Then, the mature collagen molecules self-assemble into fibrils, on the cell surface 13 
and/or in the extracellular matrix, through covalent cross-links between telopeptides and 14 
specific Triple-helical Telopeptide-Binding Regions [2] (Fig. 1). 15 
Minor fibrillar collagens of type V and XI are considered to act as nucleators, 16 
controlling the assembly of collagen fibrils, in such a way that they become mostly 17 
buried, under major fibrillar collagens I, II and III, in the core of the mature heterotypic 18 
extracellular fibril [3]. Extracellular collagens are main components of the extracellular 19 
matrix, along with proteoglycans and glycoproteins such as fibronectin and tenascin C, 20 
among others. 21 
In the adult, (pro)collagen 11A1 is present in the ocular vitreous, in the inner ear, 22 
in hyaline cartilage, and in the nucleus pulposus of the intervertebral disc [4]. In the 23 
latter, it is mainly produced by chondrocytes; in the case of the ocular vitreous, by 24 
keratocytes (corneal fibroblasts). It is also expressed by mesenchymal stem cells and 25 
osteoblasts [5-6] (Fig. 2). 26 
 4 
Under regular conditions, normal epithelial cells and quiescent fibroblasts, from 1 
diverse locations, do not express COL11A1/(pro)collagen 11A1. 2 
 3 
Regulation of the expression of COL11A1/(pro)collagen 11A1 4 
So far, two transcription factors have been reported to interact with the 5 
COL11A1 promoter. Matsuo et al. [7] and Hida et al. [8] have shown that the 6 
transcription factor NF-Y regulates the proximal promoter activity of the COL11A1 7 
gene in both cartilage and non-cartilage cells. Lymphocyte enhancer-binding factor 1 8 
(Lef1), which participates in the Wnt signalling pathway, and is important in osteoblast 9 
maturation [9], indirectly activates COL11A1. 10 
 Human mesenchymal stem cells (HMSCs), upon exposure to TGF-β1, 11 
differentiate to carcinoma-associated fibroblast-like cells and up-regulate their 12 
COL11A1 expression [10-12]. In line with this, in fibroblasts, it was confirmed that 13 
TGF-β signalling activates the transcription of the COL11A1 gene [13]. Recently, TGF-14 
β1 has been shown to up-regulate NF-Y and to modulate its binding to the COL11A1 15 
promoter, resulting in induction of COL11A1 mRNA [14]. Similarly, the activation of 16 
the Hedgehog (Hh) pathway increases the expression of COL11A1 [15].   17 
 In cancer-associated stromal cells, several signalling activation pathways, such 18 
as the TGF-β1, Wnt or Hh, have been identified to be active [16-19]. The expression of 19 
WISP-1, a downstream mediator of the Wnt signalling pathway has been found to be 20 
correlated with the expression of COL11A1 in sporadic colorectal carcinomas [20]. 21 
Activation of Wnt signalling in stroma from pancreatic cancer is also associated to high 22 
COL11A1 expression [21]. Hh signalling promotes desmoplasia and is restricted to the 23 
stromal compartment in pancreatic cancer [22-23]. 24 
 5 
The COL11A1 gene is expressed in mesenchymal-type/soft tissue human 1 
tumours such as rhabdomyosarcoma, chondrosarcoma, fibrosarcoma, osteosarcoma or 2 
Ewing´s sarcoma [24-25], as well as in solitary fibrous tumours [26].  3 
  A high expression of COL11A1 has been found as well in at least some human 4 
gliomas/glioblastomas, especially of high-grade; these tumours are thought to be 5 
derived from mesenchymal stem cells [27-30]. 6 
Keloids are benign dermal fibroproliferative tumours, characterised by dense 7 
nodules of collagens and fibroblasts; the TGFβ/Smad pathway is paramount in this 8 
disease. COL11A1 has been found to be overexpressed in human keloid fibroblasts 9 
related to normal skin fibroblasts [31-33]. 10 
In scleroderma skin, another condition with extensive fibroblast activation and 11 
up-regulation of the TGFβ and Wnt signalling pathways, the overexpression of 12 
COL11A1 has also been reported [34]. 13 
Thus, according to all these observations, COL11A1 expression is mainly 14 
restricted to mesenchyme-derived cells (Fig. 2). 15 
 16 
COL11A1/(pro)collagen 11A1 expression as biomarker of carcinoma-17 
associated stromal cells and carcinoma progression 18 
Classically, fibroblasts are described as spindle-shaped stromal cells, which 19 
express mesenchymal biomarkers such as VIM/vimentin. 20 
They can be activated under a number of conditions, and they express some 21 
additional biomarkers, such as fibroblast activation protein (FAP).  22 
One of the conditions which leads to the activation of fibroblasts is their 23 
association to malignant tumours. They are then generically called cancer-associated 24 
fibroblasts (CAFs), a heterogeneous group which includes various stromal cell types, 25 
 6 
which along with the accompanying extracellular matrix components, build up the 1 
desmoplastic reaction. According to Togo et al., 2013 [35], “Several different markers, 2 
such as α-SMA, tenascin-C (TN-C), periostin (POSTN), neuron-glial antigen2 (NG2), 3 
PDGFRα/β, fibroblast activated protein (FAP), palladin  and podoplanin are reported to 4 
be useful for detecting activated stromal fibroblast populations in CAFs”; however, in 5 
strictu sensu, some of these markers are not exclusive to CAFs.  6 
α-SMA is a general biomarker of myofibroblasts, either resting or activated. 7 
Tenascin C is highly expressed in tissue repair and chronic inflammation [36]. Periostin 8 
is expressed by airway epithelial cells [37]. In the adult intestine, NG-2/CSPG4/MCSP 9 
expression is observed within myofibroblasts and pericytes [38]. PDGFRα/β is also 10 
expressed by fibroblasts of the idiopathic pulmonary fibrosis [39]. FAP has increased 11 
expression during tissue damage, wound healing, fibrosis and inflammation [40]. 12 
According to Rönty [41], palladin is widely expressed in both epithelial and 13 
mesenchymal tissues, in muscle cells and in non-muscle cells. As shown by Schacht et 14 
al. [42], the lymphatic marker podoplanin is expressed by different cell types, and by 15 
alveolar epithelial type I cells in lung. Some other markers, such as Fibroblast Surface 16 
Protein and fibroblast specific protein-1 (FSP-1)/S100A4, are not either specific of CAFs. 17 
Under normal regular conditions, COL11A1/(pro)collagen 11A1 is not expressed 18 
in stromal cells of head and neck, breast, lung, stomach, liver, pancreas and colon; and it 19 
is almost absent in benign pathological processes such as breast hyperplasia, sclerosing 20 
adenosis [43], idiopathic pulmonary fibrosis, cirrhosis [44], pancreatitis [45], 21 
diverticulitis, and inflammatory bowel disease [46]. 22 
  In invasive carcinomas, the extracellular collagens are key players of tumour 23 
behaviour and are subjected to continuous remodelling in such a way that they both 24 
 7 
inhibit and promote tumour progression depending on the stage of tumour development 1 
[47]. 2 
COL11A1/(pro)collagen 11A1 is highly expressed by activated stromal cells of 3 
the desmoplastic reaction of human invasive carcinomas of oral cavity/pharynx [48], 4 
head and neck [49-50], breast [43, 51-55], lung  [56-60], esophagus [61], stomach [62-5 
63], pancreas [44, 64-66], colon [20, 67-71], and ovary [14, 72] (Fig. 2). In these 6 
scenarios, the expression of COL11A1/(pro)collagen 11A1 is correlated with carcinoma 7 
aggressiveness and progression, and lymph node metastasis (Table 1). 8 
According to Vecci et al.  [62],  COL11A1 was the gene with the overall highest 9 
fold-change in advanced gastric cancer in comparison with early gastric cancer. These 10 
observations were confirmed later on by Zhao et al. [63] as COL11A1 was found to be 11 
expressed by stromal cells in the vicinity of developing carcinoma in situ in stomach, 12 
increasingly with the progression of the carcinoma, allowing to distinguish between 13 
premalignant and malignant lesions.  14 
Similarly, Freire et al. [55], Stuetz et al. [73], Ma et al. [74], Lee et al.  [75], 15 
Castellana et al. [76], and Vargas et al. [77], reported that COL11A1/(pro)collagen 11A1 16 
is overexpressed in invasive ductal carcinoma (IDC) of the breast relative to ductal 17 
carcinoma in situ (DCIS). 18 
The expression of COL11A1 has also been shown to be associated with 19 
progression and poor survival of ovarian cancer patients [14, 72]. Based on in vitro 20 
observations, Sok et al. [50] reached similar conclusions regarding head and neck 21 
squamous cell cancer growth and invasion. More recently, Galván et al. [71] found that 22 
the immunodetection of procollagen 11A1 is associated with the development of distant 23 
metastases and advanced Dukes staging of human colon adenocarcinoma. 24 
 8 
Through co-immunostainings on pancreatic ductal adenocarcinoma samples, 1 
procollagen 11A1+ cells have been shown to express some other mesenchymal markers, 2 
such as vimentin, α-SMA or desmin in different proportions [66], which confers to them 3 
an “activated myofibroblast-like” phenotype. In all the different types of human 4 
invasive carcinomas so far studied, these cells are mainly peritumoral, located around 5 
the tumor foci. It is intriguing that only a fraction of the peritumoral spindle-shaped α-6 
SMA+ myofibroblast-like cells are procollagen 11A1+. Since it has been shown that 7 
some carcinoma-associated stromal cells are in part derived from mesenchymal 8 
progenitors and some of these progenitors express COL11A1/(pro)collagen 11A1, it has 9 
been suggested that peritumoral procollagen 11A1+ cells could be a more especialized 10 
subpopulation of activated myofibroblasts [71].   11 
Although COL11A1 has been reported to be expressed to some extent by 12 
vascular smooth muscle cells [78] and tumour endothelial cells [79],  immunostaining 13 
of blood vessel walls has never been observed with the highly specific anti-human 14 
procollagen 11A1 DTMX1/1E8.33 mAb  [54, 55, 66, 71]. 15 
 16 
COL11A1/(pro)collagen 11A1 in epithelial-to-mesenchymal transition 17 
(EMT) and metastases 18 
At present, there are three recognized subtypes of “Epithelial-to-Mesenchymal 19 
Transition” (EMT) [80-81]. Type 3 EMT occurs at the invasive front of carcinomas in 20 
such a way that carcinoma cells lose adhesiveness and acquire motility and migration 21 
capabilities. Traits associated with a Type 3 EMT are the acquisition of a spindle shape, 22 
the up-regulation of vimentin (VIM), and the “cadherin switching”, consisting in the 23 
progressive loss of E-cadherin (CDH1) and the increase in N-cadherin and OB-cadherin 24 
or cadherin-11 (CDH11) expression. Together with this, EMT is also associated with 25 
 9 
the up-regulation of some transcription regulators such as SNAI1 (Snail), SNAI2 (Slug), 1 
TWIST1 (Twist) and ZEB2 (SIP1) [81-82]. 2 
It remains a matter of speculation and controversy what the origin and/or nature 3 
of the cells is which, at the front of human invasive carcinomas, express 4 
COL11A1/(pro)collagen 11A1 [72, 77, 83-84];  this aspect warrants further detailed 5 
study  (see more below). 6 
 The development of distant metastases is the major cause of death from some 7 
carcinomas. These metastases originate from small tumour emboli, which separate from 8 
the primary tumour mass, and, through bloodstream or lymphatics, reach and nestle into 9 
another body location. These emboli are not usually accompanied by stromal 10 
components but, in the establishment of pancreatic cancer metastasis, the co-migration 11 
of pancreatic stellate cells and tumour cells has been demonstrated [85]. 12 
Transcription profiling observations from circulating breast and prostate cancer 13 
cells indicate that these cells do not express COL11A1; in contrast, expression of 14 
cadherin-11 – a surface adhesion molecule, which establishes interactions with stromal 15 
cells for anchorage and nesting of distant metastases – has been shown to be associated 16 
with a circulating and metastasizing phenotype of these cancer cells [86-89]. 17 
 The overexpression of COL11A1 has been correlated with a multi-cancer 18 
metastasis-associated gene expression signature [90], and with lymph node metastasis 19 
of non-small lung cancer [57]. Reports on the differential expression of COL11A1 20 
between primary breast tumours and lymph node metastases have pointed toward a 21 
higher expression in the primary tumours [91-93]. 22 
These studies did not pay especial attention to the kind of cells which express 23 
COL11A1 in metastases; and moreover, so far there have not been detailed reports on 24 
 10 
the immunodetection of (pro)collagen 11A1 in metastases of human invasive 1 
carcinomas. 2 
While COL11A1/(pro)collagen 11A1+ cells seem to be predominantly activated 3 
stromal cells in the primary tumour, some observations indicate that carcinoma-derived 4 
cells, with high metastatic capabilities, can express COL11A1 [94-95]. The SNU182 5 
poorly differentiated hepatocellular carcinoma cell line expresses high levels of 6 
COL11A1, along with cadherin-1 and mesenchymal markers such as vimentin, SNAI1 7 
(Snail), SNAI2 (Slug), TWIST1 (Twist) and TWIST2 [94]. Lung-metastatic LM2 cells, 8 
originally derived from the clear cell renal (RCC) carcinoma SN12C cell line, have been 9 
shown to have a highly up-regulated COL11A1 gene  [95]. 10 
According to the Gene Expression Atlas, ArrayExpress  E-MTAB-37 [96],  one 11 
of the human cancer cell lines with the highest COL11A1-specific mRNA expression is 12 
the large cell lung carcinoma NCI-H661. This cell line was derived from the lymph 13 
node of a patient with large cell cancer of the lung. We have assessed by 14 
immunocytochemistry that this cell line expresses high levels of procollagen 11A1 as 15 
well (Fig. 3).  16 
Therefore, in established metastases, the expression of COL11A1/(pro)collagen 17 
11A1 could originate from both the metastatic epithelial cells and/or the accompanying 18 
activated stromal cells. 19 
 20 
Conclusion 21 
In summary, under the influence of various growth factors and signalling pathways 22 
which are known to be active in carcinomas and promote COL11A1 expression, we may 23 
conclude that COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of 24 
human carcinoma-associated stromal cells and carcinoma progression. 25 
 11 
 In agreement with this, a very recent review by Raglow and Thomas [97] 1 
highlights the role of COL11A1/(pro)collagen 11A1 in cancer. 2 
 3 
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Fig. 1 Schematic drawing of collagen fibrillogenesis by fibroblasts  (adapted  from [1] 3 
and [2], with permission of BiomedCentral  and The Company of Biologists Ltd). 4 
Procollagen polypeptides are individually synthesized and then they form trimers in the 5 
cytoplasm. Once secreted, the terminal propeptides are excised, remaining the typical   6 
triple helix of the mature collagen molecule which conserves short telopeptides at both 7 
ends. Covalent cross-links through these telopeptides and specific Triple-helical 8 
Telopeptide-Binding Regions allow mature collagen molecules self-assemble into 9 
fibrils. 10 
 11 
Fig. 2  Summarized representation of COL11A1/(pro)collagen 11A1 expression in 12 
normal healthy tissues and in tumours. A reference to the putative expression of 13 
COL11A1/(pro)collagen 11A1 in neoplastic epithelial cells at the front of invasive 14 
carcinomas has been made. 15 
 16 
Fig. 3  Representative immunostainings with the anti-human procollagen 11A1 17 
DTMX1/1E8.33 mAb (cell line cultures, original magnification x400; tissue samples, 18 
original magnification x200). A) Negative staining of a human pancreatic 19 
adenocarcinoma CAPAN-1 cell line culture; B) Pancreatic ductal adenocarcinoma; C) 20 
Negative staining of a human alveolar lung carcinoma A549 cell line culture; D) Lung 21 
adenocarcinoma; E) Very positive staining of a human large cell lung carcinoma NCI-22 
H661 cell line culture; F) Head and neck squamous cell carcinoma.  In tissue samples, 23 
only peritumoral stromal cells show a strong intracytoplasmatic staining. 24 
  
 
Table 1   Up-regulated COL11A1/(pro)collagen 11A1 expression in human tumours 
Cancer type Cell type Study Up-regulation 
associated to 
References 
Soft tissue 
(rhabdomyosarcoma, 
chondrosarcoma, 
fibrosarcoma, 
osteosarcoma, 
Ewing´s sarcoma, 
solitary fibrous 
tumours) 
Mesenchymal-
type, fibroblastic 
cDNA 
microarray, 
protein 
Malignancy [24-26, 54, 84] 
Glioma/ 
glioblastoma 
Mesenchymal-
type 
cDNA 
microarray, 
protein 
High grade [27-30] 
Keloid Mesenchymal-
type, fibroblastic 
cDNA 
microarray 
Excessive 
extracellular 
matrix 
[31-33] 
Carcinoma     
Oral cavity/pharynx Not determined cDNA 
microarray 
Lymph node 
metastasis 
[48] 
Head and neck Tumour –derived 
fibroblasts, 
transformed 
epithelial cell lines 
cDNA 
microarray, 
RT-PCR,  
siRNA 
Tumour 
proliferation, 
migration and 
invasion 
[49-50] 
Breast Stromal cells, 
invading 
neoplastic 
epithelial cells 
cDNA 
microarray, 
Q-RT-PCR, 
protein 
Progression 
from ductal 
carcinoma in 
situ (DCIS) to 
invasive ductal 
carcinoma 
(IDC) 
[43, 51-55, 73-
77, 90-93] 
Lung Carcinoma-
associated 
fibroblasts 
cDNA 
microarray, 
Q-RT-PCR, 
protein 
Tumour size, 
stage, invasion, 
lymph node 
metastasis, 
poor prognosis 
[56-60] 
Esophagus  Not determined cDNA 
microarray 
Malignancy [61] 
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(continued from previous page) 
Stomach Stromal cells cDNA 
microarray, 
Q-RT-PCR 
Progression 
from 
premalignant to 
malignant 
lesions 
[62-63] 
Pancreas Carcinoma-
associated 
fibroblasts, 
pancreatic stellate 
cells 
cDNA 
microarray, 
Q-RT-PCR, 
protein 
Progression to 
ductal 
adenocarcinoma 
[44, 64-66] 
Colon  Carcinoma-
associated stromal 
cells 
cDNA 
microarray, 
Q-RT-PCR, 
protein 
Stage,  lymph 
node metastasis  
[20, 67-71] 
Ovary Tumour epithelial 
cell lines, 
carcinoma-
associated stromal 
cells, rare foci of 
tumour epithelial 
cells 
cDNA 
microarray, 
Q-RT-PCR, 
protein 
Tumour 
progression, 
lymph node 
metastasis,  
poor prognosis 
[14, 72] 
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